Summary. We studied 57 childhood acute lymphoblastic leukaemia (ALL) patients who remained in continuous complete remission after treatment according to the Dutch Childhood Leukaemia Study Group ALL-8 protocols. The patients were monitored at 18 time points during and after treatment [640 bone marrow (BM) and 600 blood samples] by use of cytomorphology and immunophenotyping for the expression of TdT, CD34, CD10 and CD19. Additionally, 60 BM follow-up samples from six patients were subjected to clonality assessment via heteroduplex polymerase chain reaction (PCR) analysis of immunoglobulin Vh-Jh gene rearrangements. We observed substantial expansions of normal precursor B cells in regenerating BM not only after maintenance therapy but also during treatment. At the end of the 2-week intervals after consolidation and reinduction treatment, B-cell-lineage regeneration was observed in BM with a large fraction of immature CD34
Summary. We studied 57 childhood acute lymphoblastic leukaemia (ALL) patients who remained in continuous complete remission after treatment according to the Dutch Childhood Leukaemia Study Group ALL-8 protocols. The patients were monitored at 18 time points during and after treatment [640 bone marrow (BM) and 600 blood samples] by use of cytomorphology and immunophenotyping for the expression of TdT, CD34, CD10 and CD19. Additionally, 60 BM follow-up samples from six patients were subjected to clonality assessment via heteroduplex polymerase chain reaction (PCR) analysis of immunoglobulin Vh-Jh gene rearrangements. We observed substantial expansions of normal precursor B cells in regenerating BM not only after maintenance therapy but also during treatment. At the end of the 2-week intervals after consolidation and reinduction treatment, B-cell-lineage regeneration was observed in BM with a large fraction of immature CD34
1 /TdT 1 B cells. In contrast, in regenerating BM after cessation of maintenance treatment, the more mature CD19
1 /CD10 1 B cells were significantly increased, but the fraction of immature CD34 1 /TdT 1 B cells was essentially smaller. Blood samples showed a profound B-cell lymphopenia during treatment followed by a rapid normalization of blood B cells after treatment, with a substantial CD10 1 fraction (10±30%). Heteroduplex PCR analysis confirmed the polyclonal origin of the expanded precursor B cells in regenerating BM. This information regarding the regeneration of BM is essential for the correct interpretation of minimal residual disease studies.
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The lymphoid compartment of bone marrow (BM) in healthy individuals contains a small fraction of early Blineage cells with immature lymphoblastic morphology or, more frequently, with more mature cytomorphological lymphocytic characteristics (Muehleck et al, 1983; Longacre et al, 1989) . These cells exhibit a precursor B-cell immunophenotype with expression of TdT, CD10 and CD34 in addition to B-lineage markers such as CD19, CD22 and/or CD79a (Janossy et al, 1979; Greaves et al, 1983; Loken et al, 1987; Hurwitz et al, 1992; Dworzak et al, 1998a) . The proportion of such cells in children can be quite marked, ranging from 5% to 15% of mononuclear cells (MNCs) in BM aspirates, and the number of early B-cell precursors progressively decreased with age in children (Caldwell et al, 1991; Rego et al, 1998; Lucio et al, 1999) .
Apparently, 80±85% of children with acute lymphoblastic leukaemia (ALL) have an early B-cell phenotype. These precursor B-ALL are generally regarded as malignant counterparts of immature precursor B cells in BM. The standard procedure for evaluating the results of treatment in ALL is cytomorphological analysis of BM and peripheral blood (PB) smears. When less than 5% of blasts are present upon this investigation, a complete remission of disease is assumed. But by cytomorphology alone, it is virtually impossible to distinguish between normal haematopoietic precursors or residual leukaemic cells (Van Dongen et al, 1996; Coustan-Smith et al, 1998) . Distinction between normal and malignant cells is particularly important for q 2000 Blackwell Science Ltd regenerating BM in precursor B-ALL cases because the levels of committed B-cell progenitors (TdT 1 or TdT 2 ) were anecdotally reported to be as high as 50% of MNCs in BM samples after treatment (Borella et al, 1972; Smedmyr et al, 1991; Fukushima et al, 1998) .
Most reports on regenerating BM after chemotherapy in ALL are based on small patient groups and concern single time points (Kluin-Nelemans et al, 1986; Van den Doel et al, 1988; Smedmyr et al, 1991; Duval et al, 1997; Fukushima et al, 1998) . To assess the normal frequencies of precursor B-cells in PB and BM during and after treatment and the potential interference of these cells with the detection of minimal residual disease (MRD), a study by morphological and immunological methods was started in 1991. We report the follow-up results of 57 precursor B-ALL patients in continuous complete remission (CCR) with a median followup time of 5 years. Significantly increased frequencies of morphologically suspicious cells with precursor B-cell immunophenotype were not only found after treatment but also during the initial treatment phases at the end of 2-week intervals in therapy. We applied heteroduplex polymerase chain reaction (PCR) analysis of immunoglobulin heavy chain (IGH) gene rearrangements in order to exclude the presence of a clonal malignant precursor B-cell population at the time of BM regeneration.
MATERIALS AND METHODS
Patients. The study group consisted of 57 ALL patients aged 0±16 years (0±5 years n 42; 6±16 years n 15). They were treated according to the Dutch Childhood Leukaemia Study Group (DCLSG) ALL-8 protocol (intake period of the 57 patients was 1991±95), which had a BFM (Berlin±Frankfurt±Mu È nster) backbone. The patients were stratified into three branches: standard risk group (SRG), medium risk group (MRG) and high-risk group (HRG), mainly according to the leukaemic cell mass (risk factor; RF) and the treatment response (Reiter et al, 1994) . Only SRG and MRG patients with precursor B-ALL were considered for this study. SRG: , 1´0 Â 10 9 /l PB blasts on day 8, RF , 0´8, no central nervous system (CNS) disease, no mediastinal mass, no T-ALL. MRG: , 1´0 Â 10 9 /l PB blasts on day 8, RF $ 0´8, or RF , 0´8 and CNS disease and/or presence of a mediastinal mass and/or T-ALL.
The first part of the induction protocol was identical for all patients. For SRG patients, the induction protocol was directly followed by the consolidation protocol. MRG patients received a 4-week longer induction treatment and continued with the consolidation protocol, after a 2-week break in therapy. After the consolidation protocol, all patients (SRG and MRG) had a 2-week interval before starting the reinduction treatment and another 2-week interval before entering maintenance therapy. Therapy ended 2 years after diagnosis. All 57 children subjected to the study were in continuous complete remission with a median follow-up time of 5 years. The median observation time by use of cytomorphology and immunophenotyping was 179 weeks for the SRG patients (n 23) and 173 weeks for the MRG (n 34) patients.
Cell samples. BM and PB samples of Dutch children with ALL were sent to the central laboratory of the DCLSG for confirmation and classification of diagnosis. Samples were sent by express mail and processed within 24 h of collection. If the diagnosis of ALL was confirmed and sufficient cells were available, the patients were followed at 18 well-defined time points (T1 to T18; see Fig 1) during and after treatment by use of cytomorphology and immunophenotyping. A total of 640 BM samples (243 SRG and 397 MRG) and 600 PB samples (227 SRG and 373 MRG) from the 57 ALL patients were analysed by these techniques. Relapsed patients were excluded from the current study. All procedures were performed according to the local guidelines of the Medical Ethics Committees and samples were obtained after informed consent.
Cytomorphology. BM and PB smears at diagnosis and during follow-up were stained by standard techniques, including May±Gru È nwald±Giemsa (all time points) and periodic acid±Schiff reagents, Sudan black B, myeloperoxidase, a combined naphthol AS-D chloroacetate esterase and a-naphthylacetate esterase (only at diagnosis).
Immunophenotyping. MNCs were isolated from BM and PB by Ficoll±Paque centrifugation (density 1´077 g/cm 3 ; Pharmacia, Uppsala, Sweden) and washed three times. Washing of cells was performed with phosphate-buffered saline supplemented with 1% bovine serum albumin (PBS/ BSA 1%, pH 7´8). Erythrocytes were lysed if necessary by 0´83% ammonium chloride. The viability was assessed by trypan blue dye exclusion and was . 85% in all samples studied. The following monoclonal antibodies (mAbs) were used: CD10 (J5) and CD19 (B4) from Beckman Coulter Corporation (Fullerton, CA, USA); CD34 from Becton Dickinson (San Jose, CA, USA); and rabbit anti-TdT antiserum from Supertechs (Bethesda, MD, USA). 
, CD19
1 and CD34 1 cells during chemotherapy (sampling points 1±10) and after treatment cessation (sampling points 11±18) for childhood ALL patients treated according to the MRG schedule of the DCLSG ALL-8 protocol. After a relatively short pause of 2 weeks during initial treatment (points 2 and 3), an increase of both immature and more mature B-cell precursor subsets is observed. After completion of treatment, a major expansion of more mature CD10 For flow cytometric immunophenotyping, the concentration of MNC suspension was adjusted to 10 7 /ml. For single labelling with CD10 and CD19, a two-step procedure was used. Therefore, 50 ml of MNC suspension was incubated (48C, 30 min) with 50 ml of the relevant mAb, washed and subsequently incubated with 50 ml of fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin (Ig) antiserum (48C, 30 min) and washed again. CD34 was used as a phycoerythrin (PE)-conjugated mAb in a onestep procedure. After labelling, a total of 15 000 cells were acquired and analysed on a FACScan flow cytometer using lysys ii software (Becton Dickinson). Gating was set on forward-(FCS) and side-scatter (SSC) parameters to exclude cellular debris. The frequency of the cells expressing the relevant marker was calculated as a percentage of MNCs analysed.
Cytocentrifuge preparations were made with a cell concentration of 10 6 /ml (50 ml per preparation), fixed in methanol (48C, 30 min), washed, incubated with 15 ml rabbit anti-TdT antiserum in a moist chamber (room temperature, 30 min), washed, subsequently incubated with 15 ml FITC-conjugated goat anti-rabbit Ig antiserum and washed again. For double TdT and CD10 detection, MNCs in suspension were labelled with CD10 and a tetramethylrhodamine isothiocyanate (TRITC)-conjugated goat anti-mouse Ig antiserum. The labelled cells were spun onto slides, fixed and subjected to TdT staining. All preparations were mounted in glycerol with 1 mg pphenylenediamine/ml and analysed on a Zeiss fluorescence microscope equipped with phase contrast facilities (Zeiss, Oberkochen, Germany) (Van Dongen et al, 1987) . At least 200 TdT-positive cells were analysed for expression of the relevant markers. If less than 200 TdT-positive cells were present, the whole slide was screened.
Southern blot analysis. DNA samples from precursor B-ALL patients were subjected to molecular analysis of the IGH gene. DNA was isolated from fresh or frozen MNC fractions as described previously (Van Dongen & Wolvers-Tettero, 1991) . Fifteen micrograms of DNA was digested with BglII or BamHI±HindIII restriction enzymes (Pharmacia), size separated in 0´7% agarose gels and transferred to Nytran-13N nylon membranes (Schleicher and Schuell, Dassel, Germany) and IGH gene configuration was analysed by hybridization of the filters with the IGHJ6 probe (Dako Corporation, Carpinteria, CA, USA) ( Van Dongen & Wolvers-Tettero, 1991; Beishuizen et al, 1993) .
PCR amplification. PCR amplification of complete IGH gene rearrangements was essentially performed as described previously (Pongers-Willemse et al, 1999; Szczepan Â ski et al, 1999a) . For identification of clonal vh-jh rearrangements at diagnosis, 0´1 mg DNA, 12´5 pmol of the 5 H and 3 H primers and 1 U Taq polymerase (PE Biosystems, Foster City, CA, USA) were used in a 100-ml PCR reaction. For analysis of follow-up samples, 1 mg DNA, 30 pmol of the 5 H and 3 H oligonucleotide primers and 2´5 U TaqGold polymerase (PE Biosystems) were used in a 100-ml PCR reaction. DNA dilutions of diagnostic BM in polyclonal MNCs were amplified in parallel to determine the sensitivity of the assay. All primers were synthesized on an ABI 392 DNA synthesiser (PE Biosystems) using the solid phase phosphotriester method. PCR conditions after an initial 10-min step of denaturation and TaqGold polymerase activation comprised: 45 s at 928C, 90 s at 608C and 2 min at 728C for 40 cycles using a Perkin-Elmer thermal cycler (PE Biosystems). After the last cycle, an additional extension step of 10 min at 728C was performed. Appropriate positive and negative controls were included. Heteroduplex analysis of PCR products. For heteroduplex analysis, the PCR products were denatured at 948C for 5 min after the final cycle of amplification and subsequently cooled to 48C for 60 min to induce duplex formation (Langerak et al, 1997; Szczepan Â ski et al, 1998) . After duplex formation, the hetero-and/or homoduplexes were immediately loaded on 6% non-denaturing polyacrylamide gels in 0´5Â Tris/boric acid/EDTA (TBE) buffer, run at room temperature and visualized by ethidium bromide staining. A 100-bp DNA ladder (Promega Corporation, Madison, WI, USA) was used as size marker.
RESULTS

BM B-cell precursors during ALL treatment
Until day 33 of the induction treatment, all patients received the same therapy. At this time (T1) the induction response of all patients was evaluated. SRG and MRG patients were found to have similarly low frequencies (0´3±2%) of cells positive for TdT, CD34, CD10 and somewhat higher percentages of CD19 1 cells (, 7%) ( Table I and Fig 1) . After this time point, SRG patients immediately entered the consolidation treatment and were evaluated at T3, just before the reinduction treatment, and again at T4, just before starting maintenance treatment. Both samples were taken after a 2-week break in the treatment. At T3, a rise in cells positive for TdT (mean 3´9^2´6%), CD34 (mean 4´6^4%), CD10 (mean 8´0^7´2%) and CD19 (mean 9´6^7´4%) was observed compared with T1. At T4, these percentages were still higher than at the end of the induction phase (T1).
In contrast to SRG patients, MRG patients had a 2-week interval in treatment after longer induction therapy. The results of this phase were evaluated at T2. Compared with SRG patients at T3 and T4, an even higher rise in cells positive for TdT (mean 9´5^6´9%), CD34 (mean 12´5^7´2%), CD10 (mean 13´0^9´4%) and CD19 (mean 12´4^9´2%) was found at T2 in MRG patients (Table I) .
During maintenance treatment (T5 to T10), the frequencies of cells positive for CD19, CD10, TdT and CD34 were similarly low (1±5%) in the SRG and MRG patients.
BM B-cell precursors after treatment cessation
The first post-treatment BM sample evaluation was taken at T11, i.e. about 3 months after stopping chemotherapy. At that time point, the CD10 1 and CD19 1 cells were found in high percentages, i.e. 29´9^15´6% and 31´6^15´9%, respectively, for SRG patients. Only minor differences were found between SRG and MRG patients (Table I and Fig 1) . Although CD34 1 (mean 5´7^2´6%) and CD10 1 /TdT 1´7^2´1  0´5^1´0  0´9^3´0  0´1^0´3  7´2^5´5  T2  14  27  2´1^1´4  12´5^7´2  9´5^6´9  13´0^9´4  8´0^6´1  12´4^9´2  T3  24  31  2´0^1´4  8´2^6´0  6´6^4´4  19´1^12´7  5´6^4´4  18´1^12´1  T4  34  32  1´8^1´4  6´1^4´6  4´6^4´2  7´2^9´1  3´4^3´7  7´4^9´3  T5  46  22  0´6^0´5  2´7^2´1  1´3^1´2  1´8^5´9  0´6^1´1  2´2^5´7  T6  59  26  0´7^0´7  3´9^2´4  1´7^1´4  1´7^4´0  0´6^0´8  1´8^2´0  T7  72  27  0´8^0´8  3´3^2´3  1´1^1´0  1´2^1´9  0´7^1´7  1´8^1´9  T8  84  27  0´9^0´7  3´5^2´2  1´4^1´3  3´2^8´4  0´7^1´0  4´2^7´5  T9  94  11  0´7^0´6  3´4^2´5  1´0^0´8  0´9^1´2  0´2^0´3  1´7^1´2  T10  102  26  1´0^0´7  3´5^5´7  1´5^1´3  2´0^8´9  0´6^0´9  3´2^7´7  T11  116  27  1´3^0´7  4´4^3´0  3´0^2´2  29´9^15´6  3´0^1´7  31´6^15´9  T12  130  21  1´0^0´7  4´6^1´9  4´1^3´6  23´8^11´3  3´4^3´1  27´6^10´4  T13  143  22  1´3^0´6  4´6^2´0  3´0^1´7  21´4^13´5  2´8^1´6  26´4^13´8  T14  157  24  1´1^0´6  4´4^1´4  2´8^2´1  18´9^9´5  2´5^1´9  25´4^11´2  T15  168  17  1´1^0´7  4´9^2´1  3´1^1´2  22´7^12´5  2´9^1´2  28´6^10´5  T16  181  15  0´9^0´6  4´1^2´3  2´4^1´6  15´4^9´0  2´3^1´6  22´1^8´6  T17  195  6  1´3^1´3  3´3^2´1  2´6^1´4  20´2^11´1  2´3^1´2  26´3^11´5  T18  207  6  1´3^0´5  4´5^1´4  3´2^1´6  23´6^12´8  3´1^1´5 cells (mean 3´8^2´1%) also slightly increased after treatment cessation, these frequencies were now significantly lower than the frequencies of CD19 1 or CD10 1 cells (Table I ). The high values for CD19 1 and CD10 1 precursor B cells were consistently found at all later time points, at least until 2 years after stopping the therapy.
PB B-cell precursors during ALL treatment and after treatment cessation The mean frequencies of PB CD19 1 cells were persistently low throughout consolidation, reinduction and maintenance treatment phases, ranging from 1% to 5% of MNCs. Moreover, the most immature TdT 1 /CD10 1 B-cell precursors were absent or very low (, 0´1%) in PB throughout the different treatment phases as well as after treatment cessation (Table II) . After chemotherapy cessation, the percentages of PB B cells rapidly increased to normal values; at T11, CD19
1 cells already comprised 15´9^7´4% in MRG patients. Interestingly, a substantial proportion (10±30%) of these CD19
1 cells (2±5% of PB MNCs) was co-expressing the CD10 molecule. The differences between SRG and MRG patients were not significant.
Southern blotting and heteroduplex PCR analysis
Southern blotting of diagnosis DNA from six patients (three SRG and three MRG) revealed clonal IGH gene rearrangements in all cases. Heteroduplex PCR analysis showed a single monoclonal Vh-Jh product in five patients and two homo-and heteroduplexes in one patient, indicating biallelic IGH gene rearrangements (Langerak et al, 1997; Szczepan Â ski et al, 1998) . The sensitivity of heteroduplex PCR analysis for these clonal markers ranged from 1% to 5%. A total of 60 BM follow-up samples were analysed, 10 per patient on average. None of the follow-up samples contained monoclonal PCR-detectable complete IGH gene rearrangements identical to those found at diagnosis. The intensity of heteroduplex smears derived from polyclonal B cells correlated with the percentages of B-lineage cells in the sample (Fig 2) . T1  5  28  0´3^0´9  0^0´2  8´6^5´5  T2  14  25  0´3^0´4  0´2^0´5  1´2^1´4  T3  24  30  0´1^0´2  0´3^0´6  3´2^2´9  T4  34  31  0´1^0´2  0´2^0´4  0´8^0´9  T5  46  22  0´1^0´1  0´1^0´3  1´3^1´9  T6  59  23  0´1^0´2  0´1^0´4  2´4^3´4  T7  72  25  0´1^0´3  0´3^0´8  1´8^1´9  T8  84  27  0^0´1  1´6^4´9  3´7^5´1  T9  94  10  0^0´1  0´2^0´4  1´6^1´6  T10  102  23  0´1^0´5  0´3^0´7  3´0^1´8  T11  116  27  0´1^0´3  4´8^4´4  15´9^7´4  T12  130  20  0´2^0´7  4´7^7´1  21´1^6´8  T13  143  19  0´1^0´1  5´1^7´8  21´3^8´4  T14  157  23  0^0´1  3´8^4´5  21´1^8´6  T15  168  15  0´1^0´3  3´2^3´8  21´5^15´3  T16  181  14  0^0´1  3´5^4´6  18´3^5´5  T17  195  6  0  2´2^2´6  23´5^14´5  T18 
DISCUSSION
The BM MNC compartment of healthy individuals contains a subset of precursor B cells characterized by the expression of markers such as CD19, CD10, TdT and CD34 (Janossy et al, 1979; Greaves et al, 1983; Loken et al, 1987) . Such cells constitute 5±15% of MNCs in BM aspirates from healthy children. Increases in the proportion of normal Bcell precursors have been reported in children with benign diseases (Longacre et al, 1989; Fukushima et al, 1998) . Even the immature CD10 1 /TdT 1 cells can occur in unusually high frequencies and may raise suspicion for malignancy, particularly in BM regenerating after chemotherapy (Smedmyr et al, 1991; Duval et al, 1997; Dworzak et al, 1997; Fukushima et al, 1998) .
Our study of 640 BM samples and 600 PB samples from a homogeneous large group of 57 precursor B-ALL patients demonstrated that even after a relatively short pause of 2 weeks during treatment regeneration of suppressed B-cell development takes place. After such short breaks in treatment, particularly immature CD10 1 /TdT 1 and CD34
1 cells can be found in BM at frequencies as high as 20% of MNCs. The type and extent of B-cell regeneration seems to be proportional to the aggressiveness of preceding treatment, as was shown by the differences in marker positivity between the two treatment arms. For example, at T3 in SRG patients, the immature TdT 1 cells comprised 3´9^2´6% of MNCs, but in MRG patients 6´6^4´4% of MNCs. Similar differences appeared to be present for CD34
1 , CD19
1 and TdT 1 /CD10 1 cells. After cessation of maintenance chemotherapy, we observed bulky polyclonal recovery of precursor B cells in BM. Three months after treatment withdrawal, the B-cell compartment markedly increased from approximately 5% to approximately 30% of BM MNCs (Table I and Fig 1) . The detected frequencies of around 30% (^16%) of BM MNCs for CD10
1 and CD19 1 cells were significantly higher than those found in healthy donors (5±15% of BM MNCs) (Caldwell et al, 1991; Rego et al, 1998) . It is not surprising to see such massive B-cell regeneration after chemotherapy for ALL bearing in mind that this type of treatment is accompanied by profound B-cell lymphopenia, which was also clearly demonstrated in this study. This is in contrast to T-cell numbers and T-cell immunophenotype in PB, which remained virtually normal (Caver et al, 1998) . Moreover, long-term survivors of ALL have been shown to lack protective antibody levels specific for common paediatric bacterial or viral pathogens, despite prior vaccinations (Smith et al, 1995) . Among regenerating B-cell progenitors in BM after maintenance chemotherapy, we observed an obvious predominance of the more mature CD19 1 /CD10 1 / TdT 2 /CD34 2 population, which is also predominant in the normal paediatric BM B-lineage cells (Lucio et al, 1999) . Furthermore, we and colleagues (Fukushima et al, 1998) found that the decline to normal percentages of CD10 1 and CD19 1 BM cells did not occur within 2 years from stopping the chemotherapy (T18).
We observed a rapid normalization of the blood B-cell counts after treatment cessation. However, a substantial subset of these CD19 1 cells (10±30%) was co-expressing CD10, which is markedly higher than normal PB, where CD19 1 /CD10 1 cells comprise less than 1% of MNCs (Ryan et al, 1984; Calado et al, 1999) . This more mature CD19 1 / CD10 1 /TdT 2 precursor B-cell population apparently reflects the massive regeneration in BM at this time point and may be perceived as the release of this more mature precursor B-cell subset into the blood during the first 2 years after treatment (Table II) . Apparently, the interaction between stromal cells and more mature CD19 1 /CD10 1 /TdT 2 precursor B cells in regenerating BM is less stringent than in immature CD19
1 /CD10 1 /TdT 1 B-cell precursors because this subset was hardly found in the PB. This also implies that the finding of an immature CD19 1 /CD10 1 /TdT 1 B-cell subset in PB of ALL patients is very suggestive of ALL cells.
The presence of early B-cell precursors in normal BM as well as their polyclonal expansion in`regenerating' BM should be taken into account when immunophenotypic MRD studies are performed in precursor B-ALL. On one hand, moderately increased frequencies of CD19 1 /CD10 1 / TdT 1 BM cells should never be directly interpreted as relapse of ALL, particularly during the high-dose treatment phases. On the other hand, substantial increase in B-cell precursors after chemotherapy, particularly with a homogenous immunophenotype, may herald a relapse of the disease (Farahat et al, 1995; Vervoordeldonk et al, 1996; Griesinger et al, 1999) . Alternatively, malignant cells in precursor B-ALL patients can be distinguished from normal early B-lineage cells based on atypical immunological characteristics. This concerns tumour-associated ectopic expression of antigens such as TdT, CD66c or NG2, crosslineage antigen expression, maturational asynchronous antigen expression, antigen overexpression or loss of markers expressed in normal B-cell precursors (Van Dongen et al, 1996; Dworzak et al, 1998b; Ciudad et al, 1999; Sugita et al, 1999) . Such characteristics can be detected with currently available four-colour flow cytometry in at least 85% of the cases (Wells et al, 1998; Campana & CoustanSmith, 1999; Lucio et al, 1999; Weir et al, 1999) .
In problematic cases, molecular studies are warranted to ensure that B-lineage cells really represent regenerating normal BM precursors and are not the first sign of an imminent relapse. For this purpose, we applied heteroduplex PCR analysis, which we routinely use for identification of clonal Ig and TCR gene rearrangements as MRD targets (Langerak et al, 1997; Szczepan Â ski et al, 1998 Szczepan Â ski et al, , 1999b . Heteroduplex PCR analysis of IGH gene rearrangements in a total of 60 remission BM follow-up samples demonstrated that B-cell precursors in regenerating BM indeed had a polyclonal origin. Furthermore, the high density of polyclonal heteroduplex smears was related to the abundance of B-cell precursors at the same time points (Fig 2) . Although heteroduplex PCR analysis has a limited sensitivity (1±5%) and cannot be used for MRD monitoring (Langerak et al, 1997) , it is sufficiently sensitive to determine clonality in samples containing high frequencies of`regenerating' B cells. Thus, heteroduplex PCR analysis can be easily applied to confirm the polyclonal origin of the precursor B cells in regenerating BM.
